|
Results from three phase 3 trials, suggest ixekizumab (Talz, Eli Lilly & Company) is effective through 60 weeks of treatment among patients with moderate-to-severe plaque psoriasis.
Primary endpoints. |
ADVERTISEMENT
Technology influences on aesthetics and anti-aging:
Review current and emerging trends in consultative practices, surgical techniques, and non surgical therapies.
 Read more |
|
Researchers have uncovered new pathways that control skin lightening and tanning, which could lead to a novel class of therapeutics for treating pigmentation disorders.
Is it a win? |
ADVERTISEMENT
Help for managing your psoriasis patients
Answers to common questions about biologics, handling complications and other therapeutic considerations for psoriasis — from the experts.
 Read more |
In case you missed it
Solving the ineffective acne consult
Smart use of smartphones
Hard water in home, infant eczema linked
|
Get the free app!
|
